Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer

PARP Inhibitors - Effective in Men with BRCA-Mutant Prostate Cancer - CancerConnect

Prostate cancer and bone: clinical presentation and molecular mechanisms in: Endocrine-Related Cancer Volume 30 Issue 9 (2023)

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

TRITON3 Rucaparib vs Physician's Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations - The ASCO Post

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study - European Journal of Cancer

Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association

Prostate cancer Nature Reviews Disease Primers

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer - Gonzalez - 2021 - The Journal of Pathology: Clinical Research - Wiley Online Library

FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI

𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 on X: ⚡️ Just RELEASED NEJM: Ph 3 trial Rucaparib mCRPC patients w/BRCA1, BRCA2, ATM after 2nd gen ARPI. ✓62 mo rPFS 11.2 mo vs 6.4 mo(Ruc vs

Articles - UROONCO Prostate Cancer

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Advances in the treatment of metastatic prostate cancer: Trends in Cancer

Accelerating precision medicine in metastatic prostate cancer